Pfizer announces new UK Managing Director

11 February 2022

Walton Oaks, 11th February 2022 - Pfizer Ltd announced today that Susan Rienow has been appointed UK Managing Director and Country Manager, taking over from Ben Osborn who has been appointed Regional President of Pfizer’s Hospital Business Unit for International Developed Markets.

Susan joined Pfizer over twenty years ago and has been leading the UK Vaccines Business Unit since June 2021, including supporting the UK Vaccines Taskforce and the UK Health Security Agency throughout the 2021-2022 Autumn/Winter booster campaign and launching the paediatric formulation of the Pfizer/BioNTech COVID-19 vaccine. Prior to this, she headed up the UK Hospital Business Unit where she led Pfizer UK’s antimicrobial stewardship efforts in collaboration with UK Government and other UK stakeholders.

Commenting on her appointment, Susan said: “I am excited and proud to assume the role of UK Managing Director at such a critical time. Not only is the company continuing to play an important role in supporting the UK Government’s efforts to tackle COVID-19 but we are also looking to apply key pandemic learnings beyond COVID and deliver a leap forward for UK health, prosperity and resilience. By partnering with stakeholders across the life sciences and adopting a mission-led ethos, we believe we can help address other major healthcare challenges.”

Ben successfully led the UK Company for over three years. During this time, he oversaw the first worldwide supply agreement and regulatory authorisation for the Pfizer/BioNTech COVID-19 vaccine and has continued to support its ongoing delivery into the UK over the past 14 months. In his capacity as UK Managing Director and as President of the Association of the British Pharmaceutical Industry (ABPI), he has worked to highlight the health and economic value of the life sciences sector and the importance of environmental sustainability, as well as underscore the need to improve access to innovative medicines for UK patients.

Commenting on the experience Ben said: “It has been an honour and a privilege to lead Pfizer here in the UK and particularly over the last 18 months through such historic and unprecedented times. While the COVID-19 pandemic has undoubtedly been a tragedy, it has also brought out the best in humanity and shown what can be achieved when governments, health services, regulators and life science companies all work together for human health. It’s vital that we maintain this partnership approach both now and in the future.”

Ben continues to be based in the UK and will remain as ABPI President until April 2022.

 

ENDS

 

For all media enquiries, please contact:
Pfizer UK Press Office
Tel: 0845 300 8033
Email: [email protected]

 

About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. In the UK, Pfizer has its business headquarters in Surrey and is a major supplier of medicines to the NHS. To learn more about our commitments, please visit us at www.pfizer.co.uk or follow us on Twitter (@Pfizer_UK), Facebook (@PfizerUK) and Instagram (@pfizeruk).

 

PP-PFE-GBR-4367 / February 2022